Search results for "610"

showing 10 items of 1353 documents

Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology.

2021

Abstract Asymptomatic anthracosis is the accumulation of black carbon particles in adult human lungs. It is a common occurrence, but the pathophysiologic significance of anthracosis is debatable. Using in situ high mass resolution matrix-assisted laser desorption/ionization (MALDI) fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometry imaging analysis, we discovered noxious carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines, or aromatic amines, in a series of 330 patients with lung cancer in highly variable and unique patterns. The characteristic nature of carbon-bound exogenous compounds had a strong association wi…

Cancer ResearchLung NeoplasmsNitrosaminesDNA damageCarcinogenesismedicine.disease_causeMass SpectrometryTobacco UseMetabolomeTumor MicroenvironmentMedicineHumansCarcinogenesis; Carcinoma Squamous Cell/chemically induced; Carcinoma Squamous Cell/metabolism; Carcinoma Squamous Cell/pathology; Humans; Idiopathic Pulmonary Fibrosis/chemically induced; Idiopathic Pulmonary Fibrosis/metabolism; Idiopathic Pulmonary Fibrosis/pathology; Lung Neoplasms/chemically induced; Lung Neoplasms/metabolism; Lung Neoplasms/pathology; Mass Spectrometry; Metabolome; Nitrosamines/adverse effects; Polycyclic Aromatic Hydrocarbons/adverse effects; Retrospective Studies; Tobacco Use; Tumor MicroenvironmentPolycyclic Aromatic HydrocarbonsLung cancer610 Medicine & healthRetrospective StudiesAnthracosisLungbusiness.industrymedicine.diseasePathophysiologyIdiopathic Pulmonary Fibrosismedicine.anatomical_structureOncologyTumor progressionCancer researchCarcinoma Squamous CellMetabolome570 Life sciences; biologybusinessCarcinogenesis
researchProduct

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

1996

Antigenic peptides derived from several differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs). To examine their potential role in tumour-directed immune responses in vivo, we determined CTL reactivity against seven antigenic peptides derived from the Melan A/MART-1, tyrosinase and gp100/Pmel17 antigens in the peripheral blood of 10 HLA-A2+ healthy controls and 26 HLA-A2+ melanoma patients. The influenza matrix peptide (GILGFVFTL) presented by HLA-A2.1 was used as a control peptide. CTL reactivity was assessed in a mixed lymphocyte 'peptide' culture assay. Reactivity against Melan A/MAR…

Cancer ResearchLymphocyte10050 Institute of Pharmacology and Toxicology610 Medicine & healthDermatologyPeripheral blood mononuclear cell2708 DermatologyMART-1 AntigenImmune systemMelanocyte differentiationAntigenAntigens NeoplasmTumor Cells CulturedmedicineHumansCytotoxic T cell1306 Cancer ResearchAmino Acid SequenceMelanomaneoplasmsMembrane GlycoproteinsMonophenol Monooxygenasebusiness.industryMelanomaProteinsmedicine.diseaseAntigens DifferentiationNeoplasm ProteinsCTL*medicine.anatomical_structureOncologyImmunology570 Life sciences; biology2730 OncologybusinessT-Lymphocytes Cytotoxicgp100 Melanoma AntigenMelanoma Research
researchProduct

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice

2003

Abstract Purpose The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied. Methods and materials Anemia was induced by total body irradiation ([TBI], 2 × 4 Gy) of mice before tumor implantation into the subcutis of the hind leg. The development of anemia was prevented by rhEPO (750 U/kg s.c.) given 3 times weekly starting 2 weeks before TBI. Fourteen days after fractionated TBI (tumor volume of approx. 40 mm 3 ), single-dose irradiation of the tumor with varying doses was performed so that in full dose–response relationship for the probability of tumor cure was obtained. Results Radiation-i…

Cancer ResearchPathologymedicine.medical_specialtyAnemiamedicine.medical_treatmentTransplantation HeterologousDrug Evaluation PreclinicalUrologyMice NudeHindlimbRadiation ToleranceHemoglobinsMicemedicineAnimalsHumansRadiology Nuclear Medicine and imagingRadiosensitivityddc:610ErythropoietinRadiationbusiness.industryAnemiaSarcomaHypoxia (medical)Total body irradiationmedicine.diseaseCell HypoxiaRecombinant ProteinsRadiation therapyRadiation Injuries ExperimentalOncologyErythropoietinDose Fractionation RadiationHemoglobinmedicine.symptombusinessNeoplasm TransplantationWhole-Body Irradiationmedicine.drug
researchProduct

Registration of childhood cancer: Moving towards pan-European coverage?

2015

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration. Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organi…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentChildhood cancerPopulation610 Medicine & healthWorld Health OrganizationNeoplasmsEnvironmental healthHumansMedicinemedia_common.cataloged_instance1306 Cancer ResearchEuropean UnionRegistriesAge of OnsetEuropean unionChildeducationmedia_commoneducation.field_of_studyData collectionbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancer10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseaseEuropeYears of potential life lostOncologyChild PreschoolData qualityPractice Guidelines as Topic2730 OncologybusinessEuropean Journal of Cancer
researchProduct

Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.

2011

Breast cancer is the most common cancer and the second leading cause of cancer death in industrialized countries. Systemic treatment of breast cancer is effective at the beginning of therapy. However, after a variable period of time, progression occurs due to therapy resistance. Artesunate, clinically used as anti-malarial agent, has recently revealed remarkable anti-tumor activity offering a role as novel candidate for cancer chemotherapy. We analyzed the anti-tumor effects of artesunate in metastasizing breast carcinoma in vitro and in vivo. Unlike as expected, artesunate induced resistance in highly metastatic human breast cancer cells MDA-MB-231. Likewise acquired resistance led to abol…

Cancer ResearchPhytochemistryPhytopharmacologyCancer TreatmentArtesunateApoptosisElectrophoretic Mobility Shift AssayDrug resistanceNude MiceMetastasischemistry.chemical_compoundMiceMolecular Cell BiologyDrug DiscoveryBreast TumorsBasic Cancer ResearchMedicinebcl-2-Associated X ProteinMultidisciplinaryQRNF-kappa BArtemisininsChemistryOncologyMedicineFemaleMatrix Metalloproteinase 1Breast carcinomamedicine.drugResearch Article570Drugs and DevicesDrug Research and DevelopmentCell SurvivalScienceMice Nude570 Life SciencesBreast NeoplasmsTumor Cell Line610 Medical Sciences MedicineBreast cancerComplementary and Alternative MedicineCell Line TumorAnimalsHumansDoxorubicinBiologyNeoplasm Drug Resistancebusiness.industryCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseaseXenograft Model Antitumor AssaysTranscription Factor AP-1chemistryTumor progressionArtesunateDrug Resistance NeoplasmCancer cellImmunologyEthnopharmacologyCancer researchbusinessPloS one
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion

2021

Radiochemical conversion is an important term to be included in the "Consensus nomenclature rules for radiopharmaceutical chemistry". Radiochemical conversion should be used to define reaction efficiency by measuring the transformation of components in a crude reaction mixture at a given time, whereas radiochemical yield is better suited to define the efficiency of an entire reaction process including, for example, separation, isolation, filtration, and formulation. (C) 2020 Elsevier Inc. All rights reserved.

Cancer ResearchRadiochemistryNomenclatureRadiochemical conversionChemistryRadiochemistry610 Medicine & health10181 Clinic for Nuclear MedicineTerminology030218 nuclear medicine & medical imagingNuclear chemistryRadiochemical yield03 medical and health sciences0302 clinical medicineddc:5701313 Molecular Medicine030220 oncology & carcinogenesisYield (chemistry)2741 Radiology Nuclear Medicine and ImagingMolecular Medicine1306 Cancer ResearchRadiology Nuclear Medicine and imagingRadiopharmaceutical sciencesConsensus guidelinesNuclear Medicine and Biology
researchProduct

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

2014

Introduction More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers. Methods We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen re…

Cancer ResearchReceptor ErbB-2Genes BRCA2BRCALOCIGenes BRCA1MODIFIERSVARIANTSErbB-2610 Medical sciences MedicineDuctalReceptorsMedicine and Health SciencesINVESTIGATORSBreastskin and connective tissue diseasesProgesteroneMedicine(all)Carcinoma Ductal BreastMiddle AgedAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2; Cancer Research; OncologyOncologyReceptors EstrogenTUMOR SUBTYPESFemaleReceptors ProgesteroneReceptorResearch ArticleAdultHeterozygote610Breast NeoplasmsMEDULLARY CARCINOMAOVARIAN-CANCERLobularHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONAllelesAgedNeoplasm StagingAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2CONSORTIUMCarcinomaBRCA1EstrogenBRCA2Carcinoma LobularESTROGEN-RECEPTORGenesNeoplasm GradingBreast Cancer Research
researchProduct

Cohort Profile:The Socioeconomic Consequences in Adult Life After Childhood Cancer in Scandinavia (SALiCCS) Research Programme

2021

IntroductionThe growing number of survivors of childhood cancer, with many years of life ahead, demonstrates the increasing clinical and public health relevance of investigating the risks of social and socioeconomic impairment after a childhood cancer diagnosis and the life-saving treatment. To enrich understanding of the mental, social and socioeconomic difficulties that childhood cancer survivors may face during their life-course, identify particularly vulnerable survivors and overcome the limitations of previous research, we initiated the Socioeconomic Consequences in Adult Life after Childhood Cancer in Scandinavia (SALiCCS) research programme.MethodsThis Nordic cross-border research pr…

Cancer Researchchildhood cancer survivorsDenmark3122 CancersChildhood cancer610 Medicine & healthsocial and socioeconomic outcomes03 medical and health sciences0302 clinical medicine3123 Gynaecology and paediatrics360 Social problems & social servicesMedicine030212 general & internal medicineSocioeconomic statusRC254-282FinlandOriginal ResearchSwedenbusiness.industry1. No povertyNeoplasms. Tumors. Oncology. Including cancer and carcinogensregister-based research3. Good healthAdult lifeOncology030220 oncology & carcinogenesisCohortfamily lifebusinesssurvivorshipDemography
researchProduct

Childhood cancer:Survival, treatment modalities, late effects and improvements over time

2021

Since the 1960s, paediatric oncologists have gradually become better organised in large study groups and participation in clinical trials is today considered as the standard of care, with most children with cancer in Europe and North America being enrolled on available treatment protocols. Chemotherapy is nowadays the main element of therapy, but irradiation is still required for some patients. With the advent of multimodality therapy and supportive care, five-year cancer survival exceeds 80 % in most European and North American countries today. The substantial improvements in survival led to a constantly growing population of childhood cancer survivors. Concerns regarding the risk of late …

Cancer Researchmedicine.medical_specialtyTime FactorsSurvivalEpidemiologyPopulationMultimodality TherapySurvivorshipSocial and socioeconomic conditions03 medical and health sciencesSomatic late effects0302 clinical medicineQuality of life (healthcare)NeoplasmsSurvivorship curvemedicineHumans030212 general & internal medicineChild610 Medicine & healthIntensive care medicineeducationSocioeconomic statusClinical Trials as Topiceducation.field_of_studybusiness.industryCancerTemporal changesmedicine.diseaseCombined Modality TherapySurvival AnalysisMental healthSurvivor cohortsEuropeClinical trialTreatment OutcomeOncology030220 oncology & carcinogenesisCancer treatmentNorth AmericaMental late effectsbusinessChildhood cancer360 Social problems & social services
researchProduct